arrow
G

Guido Giordano

policlinico riuniti
H指数:24
被引数:1,980

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real-world study

胆道癌患者接受化疗免疫疗法后的预后分层:一项回顾性多中心真实世界研究

Cancer
IF5.1
2026-09-160
PRE
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting

根据TOPAZ-1研究入组标准评估顺铂、吉西他滨和度伐利尤单抗的疗效:一项真实世界环境下的全球性大规模分析

2026-08-160
PRE
Prognostic impact of variants of uncertain significance (VUS) in BRCA genes and homologous recombination repair (HRR) genes in prostate cancer: a real-world multicenter study

BRCA基因和同源重组修复(HRR)基因中意义不明的变异(VUS)对前列腺癌预后的影响:一项真实世界多中心研究

2026-08-040
OA
Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study

度伐利尤单抗联合吉西他滨为基础的化疗方案在晚期胆道癌中的应用:TOURMALINE IIIb期研究的主要结果

2026-07-060
OAAI
Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection

吉西他滨联合 nab-紫杉醇后转移性胰腺癌的二线化疗:比较结果及人工智能指导的治疗选择

2026-04-010
PRE
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab

接受顺铂、吉西他滨和度鲁特韦治疗的胆道癌患者中,转移部位对预后的影响

2026-02-270
PRE
Real-world Predictors of Early Mortality and Treatment Discontinuation in HCC Patients Treated with Atezolizumab-Bevacizumab

接受阿替利珠单抗-贝伐珠单抗治疗的HCC患者早期死亡和治疗中断的预测因素

2026-01-200
PRE
CDK4/6 Inhibitors in Patients Aged 80 and Older with HR+/HER2− Metastatic Breast Cancer: A Real-World Multicenter Study

CDK4/6抑制剂在80岁及以上HR+/HER2−转移性乳腺癌患者中的应用:一项真实世界多中心研究

2025-10-130
OAAI
Genomic Pathway Alterations and Their Prognostic Impact in Biliary Tract Cancer: Insights from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab

基因组通路改变及其在胆道癌中的预后影响:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的跨国队列的见解

2025-10-030
PRE
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population

接受顺铂、吉西他滨和度伐利尤单抗治疗的晚期胆道癌患者中分子改变的影响:一项大型、真实世界、全球性人群研究

2025-09-011
PRE
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience

真实世界结局与分子分型:肺转移性去势抵抗性前列腺癌患者的长期多中心研究经验

2025-06-010
OAAI
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients.

意大利多中心胰腺癌患者癌症易感性基因的种系致病变异。

2024-09-010
PRE
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population

Durvalumab联合吉西他滨和顺铂治疗晚期胆道癌: 大量现实世界人口

2024-09-013
PRE
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study
2024-05-019
PRE
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care

局部/局部晚期疾病的初始管理方法对于指导转移性去势抵抗性前列腺癌的治疗至关重要

2024-02-121
PRE